SCHEMBL29411430

SCHEMBL29411430

CCn1nc(C)cc1C(=O)NCCCc1ccc(-c2ccccc2F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.47
MAPT P10636 5/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
STING1 Q86WV6 3/20 0.42
F10 P00742 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TSHR P16473 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
KMT2A Q03164 1/20 0.41
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
F2 P00734 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
LMNA P02545 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21045081 1.00 HDAC6 (0.47) HDAC6MAPTSMN1; SMN2STING1F10
SCHEMBL29411543 0.88 MAPT (0.47) HDAC6MAPTSMN1; SMN2F10L3MBTL1
SCHEMBL21045124 0.88 MAPT (0.47) HDAC6MAPTSMN1; SMN2F10L3MBTL1
SCHEMBL21045118 0.79 POLB (0.50) MAPTSMN1; SMN2L3MBTL1TSHRMEN1
SCHEMBL29411496 0.79 POLB (0.50) MAPTSMN1; SMN2L3MBTL1TSHRMEN1
SCHEMBL21045463 0.78 GRIA4 (0.44) HDAC6MAPTSMN1; SMN2TSHRMEN1
SCHEMBL29411603 0.78 LIPG (0.45) HDAC6MAPTSMN1; SMN2F10L3MBTL1
SCHEMBL21045139 0.78 LIPG (0.45) HDAC6MAPTSMN1; SMN2F10L3MBTL1
SCHEMBL21045157 0.78 HDAC3 (0.56) HDAC6MAPTSMN1; SMN2ASAH1
SCHEMBL29411625 0.78 GRIA4 (0.44) HDAC6MAPTSMN1; SMN2TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188035-A1 TUBULIN INHIBITORS LIN BIOSCIENCE LLC (US) 2025-06-12 US disclosed
US-12247010-B2 Tubulin inhibitors LIN BIOSCIENCE INC. (TW) 2025-03-11 US disclosed
US-20220089539-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089539-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB HDAC6 30/4885MAPT 24/4885SMN1; SMN2 1062/4885
US-12247010-B2 Tubulin inhibitors TUBB3, TUBB1, TUBB HDAC6 30/4885MAPT 24/4885SMN1; SMN2 1062/4885
US-20250188035-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB HDAC6 30/4885MAPT 24/4885SMN1; SMN2 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.